Core Viewpoint - Nutex Health Inc. is facing a class-action lawsuit for allegedly engaging in deceptive billing practices to inflate its financial results, which has led to significant investor losses [1][11]. Group 1: Allegations and Legal Actions - The lawsuit claims that Nutex collaborated with HaloMD to submit ineligible insurance claims, misleading shareholders and resulting in substantial financial losses [1][2]. - Nutex's revenue model is criticized for being built on unstable foundations, with financial statements that misrepresented the company's operations [3]. - The class-action suit seeks to recover damages for investors who acquired Nutex securities during the alleged misrepresentation period, arguing that public disclosures were materially misleading [11]. Group 2: Financial and Operational Concerns - The complaint highlights that Nutex's reliance on arbitration reimbursements poses a significant risk, with suggestions that the company's stock could collapse to penny-stock levels [5]. - Nutex is accused of misclassifying stock-based compensation obligations, distorting its financial position [6]. - Following a report from Blue Orca Capital, Nutex shares dropped over 10%, indicating investor unease regarding the company's financial practices [5]. Group 3: Market Reactions and Company Responses - After the allegations surfaced, Nutex's shares experienced a 16.39% drop following the announcement of a delay in submitting its Form 10-Q due to "non-cash accounting adjustments" [7]. - On August 21, Nutex disclosed that its Audit Committee found prior financial statements required restatement, necessitating revisions to obligations tied to hospital development [8]. - Nutex's response to the allegations has been criticized for not directly addressing the core accusations raised by Blue Orca [9].

Core Viewpoint - Nutex Health Inc. is facing legal scrutiny due to a class-action lawsuit alleging deceptive billing practices that artificially inflated its financial results [1][2] Group 1: Legal Allegations - The lawsuit claims Nutex collaborated with HaloMD to submit ineligible insurance claims, misleading shareholders and causing significant financial losses [1][2] - Allegations include a systematic effort to exploit the insurance arbitration process, submitting thousands of questionable claims to extract outsized reimbursements [2][3] - The complaint argues that Nutex's revenue model is unstable and that financial statements misrepresented the company's operations [2] Group 2: Market Reaction - Following a report by activist short-seller Blue Orca Capital, Nutex shares dropped over 10%, reflecting investor concerns about the company's reliance on arbitration reimbursements [3][4] - After Nutex announced a delay in its Form 10-Q filing, shares plunged 16.39%, closing at $92.91 [6] Group 3: Financial Reporting Issues - The lawsuit asserts that Nutex misrepresented its progress in addressing internal control deficiencies, particularly in misclassifying stock-based compensation obligations [5] - On August 21, Nutex disclosed that its Audit Committee found prior financial statements required restatement due to incorrect classification of obligations [7] Group 4: Investor Impact - The class-action suit seeks damages for investors who acquired Nutex securities during the alleged misrepresentation period, claiming public disclosures were materially misleading [9] - Hagens Berman is investigating whether Nutex's business model relied on questionable arbitration tactics and if its financial reporting misled investors [10]

Core Viewpoint - Nutex Health Inc. is facing legal scrutiny due to a class-action lawsuit alleging deceptive billing practices that artificially inflated its financial results [1][10] Group 1: Legal Allegations - The lawsuit claims Nutex collaborated with HaloMD to submit ineligible insurance claims, misleading shareholders and causing significant losses [1][2] - Allegations include a systematic effort to exploit the insurance arbitration process, submitting thousands of questionable claims to extract outsized reimbursements [2][4] - The revenue model of Nutex is described as unstable, with financial statements failing to accurately reflect the company's operations [3] Group 2: Market Reaction - Following the release of a report by Blue Orca Capital, which accused HaloMD of a fraudulent scheme, Nutex shares dropped over 10% [4][5] - After Nutex announced a delay in its Form 10-Q submission, shares plunged 16.39%, closing at $92.91 [7] Group 3: Financial Reporting Issues - The lawsuit asserts that Nutex misrepresented its progress in addressing internal control deficiencies, particularly in misclassifying stock-based compensation obligations [6] - On August 21, Nutex disclosed that its Audit Committee determined certain prior financial statements required restatement due to incorrect classifications [8] Group 4: Investor Impact - The class-action suit seeks to recover damages for investors who acquired Nutex securities during the alleged misrepresentation period [10][11] - Plaintiffs argue that the company's public disclosures were materially misleading, leading to significant investor harm when the true financial condition was revealed [11]

Core Viewpoint - Nutex Health Inc. is facing legal scrutiny due to a class-action lawsuit alleging deceptive billing practices that artificially inflated its financial results [1][2][9] Legal Allegations - The lawsuit claims Nutex collaborated with HaloMD to submit ineligible insurance claims, misleading shareholders and causing significant financial losses [1][2] - Allegations include a systematic effort to exploit the insurance arbitration process, submitting thousands of questionable claims to extract excessive reimbursements [2][3] Market Reaction - Following the release of a report by activist short-seller Blue Orca Capital, Nutex's stock dropped over 10%, reflecting investor concerns about the company's reliance on arbitration reimbursements [3][4] Financial Misrepresentation - The lawsuit asserts that Nutex misrepresented its progress in addressing internal control deficiencies, particularly in misclassifying stock-based compensation obligations [5] - Nutex's shares fell 16.39% after the company announced a delay in its Form 10-Q filing due to "non-cash accounting adjustments" [6] Audit Findings - On August 21, Nutex disclosed that its Audit Committee determined certain prior financial statements required restatement due to incorrect classification of obligations related to hospital development [7] Investor Impact - The class-action suit seeks to recover damages for investors who acquired Nutex securities during the alleged misrepresentation period, arguing that public disclosures were materially misleading [9] Ongoing Investigations - Law firm Hagens Berman is investigating the claims against Nutex, focusing on whether the company's business model relied on questionable arbitration tactics and misleading financial reporting practices [10]

Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nutex To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nutex between August 8, 2024 and August 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212- 983-9330Â (Ext. 1310). Faruqi & Faruqi is a leading national securities law firm with office ...

Core Points - Nutex Health, Inc. is facing a class action lawsuit for investors who purchased securities between August 8, 2024, and August 14, 2025, with a deadline to file a lead plaintiff motion by October 21, 2025 [1] - Blue Orca Capital issued a short report on July 22, 2025, alleging that Nutex is exposed to litigation risk due to its association with HaloMD, which is involved in a fraudulent scheme against insurance companies [3] - Following the release of the Blue Orca report, Nutex's stock price dropped by $11.18 per share, or 10.05%, closing at $100.01 per share on the same day [3] Legal Representation - The Portnoy Law Firm is representing investors in claims related to corporate misconduct and offers complimentary case evaluations [2][4] - The founding partner of the Portnoy Law Firm has successfully recovered over $5.5 billion for investors in the past [4]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nutex To Contact Him Directly To Discuss Their Options If you suffered losses in Nutex between August 8, 2024 and August 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leadi ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nutex To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nutex between August 8, 2024 and August 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Faruqi & Far ...

Core Viewpoint - Nutex Health Inc. is facing a class action lawsuit due to allegations of securities fraud related to its dealings with HaloMD, which reportedly engaged in fraudulent activities to benefit Nutex financially [3][5]. Group 1: Allegations and Impact - On July 22, 2025, a report by Blue Orca Capital claimed that HaloMD was involved in a fraudulent scheme that resulted in significant financial losses for insurance companies, leading to a decline in Nutex's share price by approximately 10.05% [3]. - Following Nutex's announcement on August 14, 2025, regarding a delay in filing its quarterly report due to accounting adjustments, the company's share price fell by about 16.39% [4]. Group 2: Details of the Lawsuit - The lawsuit covers investors who purchased Nutex securities from August 8, 2024, to August 14, 2025, alleging that Nutex made misleading statements and failed to disclose critical information regarding its financial practices and the sustainability of its revenue [5]. - Specific allegations include that Nutex overstated its financial health, mismanaged stock-based compensation obligations, and failed to adequately address weaknesses in its internal controls over financial reporting [5].

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) HaloMD was achieving lucrative arbitration results for Nutex by engaging in a ...